SLR Capital Partners Provides $225MM Term Loan to Arcutis Biotherapeutics
Arcutis Biotherapeutics, a late-stage biopharmaceutical company focused on developing innovations in immuno-dermatology, obtained a $225 million term loan facility from funds managed by SLR Capital Partners.
December 27, 2021
Anthony Storino | Arcutis Biotherapeutics | Frank Watanabe | J. Wood Capital Advisors | Latham & Watkins | SLR Capital Partners
Ian Koplin